Life sciences companies are embracing the essential roles that real world data (RWD) and the generation of real world evidence (RWE) play in the development of new treatments for patients. Regulators, payers and pharmaceutical manufacturers alike have recognized the immense potential of RWE in accelerating the ability to answer important questions on safety and effectiveness.
The opportunity to improve clinical study design and execution is perhaps one of the most imminent and easily applied. It is no surprise that life science companies consider this realm a priority within their overall RWE strategy.
This paper will explore three areas where RWD and RWE are being applied to improve the design and execution of clinical studies: